Primary biliary cholangitis (formerly primary biliary cirrhosis) is a chronic, progressive, autoimmune, cholestatic liver disease more common in middle-aged women. It is characterized by destruction of small to medium bile ducts leading to cholestasis and frequently, end-stage liver disease.
Diagnostic features are chronic biochemical cholestasis, presence of antimitochondrial antibodies and the characteristic liver biopsy findings.


Primary%20biliary%20cholangitis Management


Annual Re-evaluation for Certain Patients

  • Patients positive for AMA, but have a normal ALP level, should have their liver biochemistry rechecked yearly
  • A small study has shown that most AMA-positive asymptomatic individuals with normal ALP eventually develop evidence of cholestasis and/or cholestatic symptoms after several years

Prevention and Treatment of Complications

  • Patients with cirrhosis and inadequate biochemical response to treatment [ie diagnosed at early age (eg <45 years), presented with advanced disease stage] have a high risk of developing PBC complications 
  • Assess PBC activity and progression with tests for albumin, total bilirubin, AST, ALT, ALP, GGT, PT every 3-6 months
  • Assess esophageal/gastric varices complication with an upper gastrointestinal endoscopy annually and liver cirrhosis with an abdominal US with or without serum alpha-fetoprotein every 6 months


  • As there is currently no recommended therapy for fatigue, patient education and counseling regarding this symptom is important 
  • Determine and treat other causes of fatigue, eg anemia, hypothyroidism, sleep disorders


  • Pruritus has a significant effect on a patient’s life and is often refractory to medical treatment
  • Lifestyle changes such as avoidance of itchy or tight clothes and use of moisturizers or emollients, tepid baths, or ice packs may be helpful


  • Cholestyramine is the main drug used to treat cholestasis-associated pruritus
  • Action: Binds bile acids in the gut lumen promoting its fecal excretion
  • Most effective in patients with intact gallbladders if taken before and after breakfast, because this is when the largest amount of bile is available for binding by the drug
  • Drug takes effect within 1-4 days of starting therapy
  • Effect is optimal with daily treatment
  • Given 2-4 hours before or after other medications because Cholestyramine can also bind other oral drugs 
  • Patients unresponsive to Cholestyramine can be given Rifampicin, opioid antagonists eg Naltrexone and Naloxone, or Sertraline


  • May be used to control mild pruritus early in the course of the disease
    • Should be used with caution in patients with cirrhosis or signs of encephalopathy because antihistamines can depress brain function further
  • Not typically very effective and most of the relief results from sedation


  • Other medications for the treatment of pruritus are Rifaximin, Dronabinol, Phenobarbital and Metronidazole
  • Newer agents include a peroxisome proliferator activator receptor (PPAR) agonists, autotaxin inhibitors and ileal bile acid reabsorption transporter inhibitors

Portal Hypertension

  • Portal hypertension may develop earlier than cirrhosis from nodular regenerative hyperplasia
  • Nonselective beta-blockers may help relieve portal hypertension
  • Patients may also benefit from shunt surgery
  • Patients should be screened endoscopically for varices upon diagnosis of PBC and every 3 years thereafter
  • Prophylactic measures to prevent bleeding should be carried out in patients with varices

Metabolic Bone Disease

  • Osteoporosis is often subtle and can only be detected by measuring bone mineral density using dual energy X-ray absorptiometry (DEXA)
  • Patient’s bone mineral density should be assessed at the time of diagnosis of PBC and every 1-2 years thereafter
  • All PBC patients should be advised to engage in regular weight-bearing exercise and if required, to stop smoking and drinking alcohol
  • Vitamin D and calcium supplementation should be given 
  • In patients with evidence of osteoporosis, bisphosphonates are of benefit
  • Estrogen hormone replacement therapy may be needed in certain patients
    • Transdermal administration may be the preferred route

Sicca Syndrome

  • Symptoms of the sicca syndrome should be elicited by direct questioning
  • Patients with dry eyes should be given artificial tears initially to prevent complications eg corneal ulceration
    • Ciclosporin or Lifitegrast can be used in patients unresponsive to other therapies 
  • Patients with dry mouth should be given saliva substitutes and undergo monitoring of oral health
  • Pilocarpine or Cevimeline can be given to patients with dry mouth or dry eyes who are unresponsive to other therapies
  • Liquids should be given with food and medications to ease swallowing
  • Lubricating jelly and moisturizers may be used in female patients with dyspareunia

Malabsorption of Fat-Soluble Vitamins

  • Replacement of fat-soluble vitamins (eg vitamin K) may be given using their parenteral or water-soluble forms
  • If bilirubin level is >2 mg/dL, monitor vitamins A, D, E and prothrombin time yearly


  • A complication of chronic cholestasis, hyperlipidemia seen in PBC is apparently not associated with increased risk of cardiovascular disease
  • Statins and fibrates may be given to patients with PBC 
    • Fibrates may occasionally cause a paradoxical increase in serum cholesterol levels

Thyroid Dysfunction

  • Thyroid-stimulating hormone should be determined at the time of diagnosis of PBC and regularly thereafter ie yearly

Raynaud’s Syndrome

  • More of an issue for patients in cold climates
  • Patient should be advised to avoid exposure of extremities to cold and to stop smoking
  • Calcium antagonists may relieve extremity symptoms but may worsen esophageal dysmotility
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Tristan Manalac, 6 days ago
Adding dapagliflozin (DAPA) and saxaglipitin (SAXA) to routine metformin treatment in type 2 diabetes (T2D) leads to a decrease in liver fat and adipose tissue, according to a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).
Stephen Padilla, 5 days ago
The distribution of body fat contributes to the risk of coronary heart disease (CHD), with the risk of cardiovascular events further increasing among individuals with low liver fat (LF) and high visceral adipose tissue (VAT) or abdominal fat, results of a recent study have shown.